Navigation Links
Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir
Date:11/21/2013

tentially shorter treatment duration, possible interferon-free regimens, improved safety and tolerability profiles and higher cure rates – physicians are eagerly awaiting these new regimens and holding off on prescribing treatment until they are part of the arsenal." 

The study also finds that at least one-third of surveyed physicians have received a patient request for one of the currently available HCV brands in the past month. Further, a subset of surveyed physicians has already received patient requests for sofosbuvir and simeprevir, suggesting that awareness of these products exists among patients even ahead of their anticipated U.S. launch later this year.

TreatmentTrends®: Hepatitis C Virus (US), Wave 2 is a report that covers the use of agents for the treatment of HCV infections. This biannual study focuses on current and future use of leading HCV treatment regimens, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs. In addition, this report assesses potential impact of regimens in development, including AbbVie's ABT-267, ABT-333 and ABT-450/r, Boehringer Ingelheim's faldaprevir and deleobuvir, Bristol-Myers Squibb's asunaprevir and daclatasvir, Gilead's ledipasivr and sofosbuvir and simeprevir. In the current wave of research, BioTrends surveyed 98 U.S. gastroenterologists, hepatologists and infectious disease specialists in September 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.b
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston
2. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
3. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
4. OPTIMIZERx Corporation Announces the Resignation of the Companys Current CEO & Chairman Mr. Shadron L. Stastney
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
7. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
8. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
9. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
10. Hepatitis C Drug Market: Forecasts for 9 Countries, Players (Current and Future) Analysis in New Research Reports
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of the "United States ... report to their offering.      (Logo: ... adhesives in the United States ... 2020 Medical device manufacturers across ...
(Date:5/28/2015)... Md. , May 28, 2015 ... it will be a supporting organization of the ... and sterilization in 2016. Johnson & ... series of high-profile superbug infections in endoscopes. J&J ... health issues between 1976 and 2003 on advances ...
(Date:5/28/2015)... Compassion & Choices today is pleased to report ... would authorize the option of medical aid in dying for ... The legislation, the End ... competent adults with six months or less to live the ... and peacefully end an unbearable dying process. A vote on ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3
... 17 The following letter is being released ... , Dear Fellow Shareholders: , We are pleased to report to you ... ever. During this difficult time we were able to complete and validate ... being able to manufacture Multikine for the Phase III clinical trial.  We ...
... , RALEIGH, N.C. , Feb. ... training solutions for the pharmaceutical and biotech industry, today announced ... and Retail Pharmacy .  The courses, developed in partnership ... to the company,s Managed Markets Excellence® Series, a ...
Cached Medicine Technology:CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6Pharmaceutical Institute Launches New Training Resources Focused on Employers and Retail Pharmacy 2Pharmaceutical Institute Launches New Training Resources Focused on Employers and Retail Pharmacy 3
(Date:5/29/2015)... 2015 National Day of Sweden , ... around the world. The celebration held in Atlanta is organized ... with SWEA (Swedish Women’s Educational Association International, Inc.). ... the Swedish-American community in Georgia. , PartnerTech is ... heritage and the long relationship between Sweden and Georgia. PartnerTech ...
(Date:5/29/2015)... Houston, TX (PRWEB) May 29, 2015 ... lorcaserin, is an FDA approved prescription diet medication. ... treatment of obesity when individuals have a BMI >30. ... BMI >27 with at least one additional weight-related health ... cholesterol. , Belviq’s main function for weight ...
(Date:5/28/2015)... May 29, 2015 Recently, KORT Richmond, 5006 ... amputees regain their quality of life. The program works with ... had one for years, but are still having difficulty. , ... 2 million people living with limb loss in the United ... – including diabetes and peripheral arterial disease – trauma (45%) ...
(Date:5/28/2015)... 2015 The USC Verdugo Hills Hospital Wound ... for a decade with a current average healing rate of ... and Wound Care Advantage to provide in-patient wound care. This ... a drop in the rate of hospital-acquired pressure ulcers from ... a complex undertaking that can frighten patients and caregivers who ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The ... to announce that the International Organization for Standardization ... Domain Group (BRIDG) Model version 3.2 as a ... its link with healthcare. This standard, which had ... (DIS) ballot, was unanimously approved on 24 April ...
Breaking Medicine News(10 mins):Health News:PartnerTech Co-Sponsors National Sweden Day Hosted by SACC-Georgia 2Health News:PartnerTech Co-Sponsors National Sweden Day Hosted by SACC-Georgia 3Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:USC Verdugo Hills Hospital Wound Care Team Provides Outstanding Healing Results 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3
... with a low-priced antibiotic, according to scientists.It causes severe ... team of scientists at the Liverpool School of Tropical ... in the advanced stages of the disease. In addition, ... Filariasis (LF) affects nearly 120 million people, usually, in ...
... Shepherd Medical Center in Oregon is providing healthy organic food ... Foods from wild salmon to local organic foods are there ... of antioxidant-rich dried cherries. , Angela Mallory, a ... for five days recently for the delivery of her son ...
... is tougher to quit menthol cigarettes than the regular ones, ... in blacks in the U.S.// ,This study was ... black smokers go for menthol cigarettes like Kool or Newport ... several historical and cultural reasons, according to the study. This ...
... increased homicide rates. However as the membership of Alcoholics Anonymous ... number of homicides. In males who consume beer and spirits, ... homicide, a new study finds. ,Results are published ... ,"It is important to try to understand the ...
... Health Department today clarified that so far no chikungunya ... Services T.K. Kuttamani said //that three death attributed to ... ,Mukundan, 71 at Vavallichira, Cherthala ded from ... Selvi, 81, of Kollekkattu also died of natural causes. ...
... the University of Virginia Health System have identified, for the ... carry the genes for nicotine// dependence (ND) in an African ... linkage and included the largest group of African Americans to ... participants in research to find genetic links to ND have ...
Cached Medicine News:Health News:Menthol cigarettes harder to quit than regular cigarettes 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 3Health News:Researchers Locate Genetic Link for Nicotine Dependence Among African Americans 2
... This third-generation immunoassay system combines ... STAT processing with a broad ... and higher volume clinical laboratories ... immunodiagnostic tests simultaneously, as well ...
Highly specific two-site antibody ELISA, which only recognises free PSA...
... Prostate-Specific Antigen (PSA) derives its name ... the prostate gland. The majority of ... other compounds. Serum concentrations of PSA ... benign prostatic hypertrophy (BPH) and prostatitis [1-3]. ...
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
Medicine Products: